• Icure Pharmaceutical’s Oct. 20 correction to its first-half 2026 report confirms continued listing, replacing disclosure that a delisting decision was pending.
• The listing review followed an Aug. 5, 2025, disclosure of embezzlement and breach-of-trust allegations.
• Treasury share cancellation deadlines were corrected to 2027 from 2026; total holdings remain 188,683 shares, or 0.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Icure Pharmaceutical Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261020000386), on October 20, 2026, and is solely responsible for the information contained therein.